SCHEMBL2961724

SCHEMBL2961724

O=C(CO)[C@@H](O)[C@H](O)CO.O=C(CO)[C@H](O)[C@H](O)CO

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.50
TSHR P16473 1/20 0.50
PDE4A P27815 1/20 0.44
LMNA P02545 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
TDP1 Q9NUW8 1/20 0.38
USP2 O75604 1/20 0.36
SLCO1B1 Q9Y6L6 1/20 0.36
OR51E2 Q9H255 1/20 0.35
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL37387 1.00 CYP2C9 (0.50) CYP2C9TSHRPDE4ALMNAL3MBTL1
SCHEMBL44299 1.00 CYP2C9 (0.50) CYP2C9TSHRPDE4ALMNAL3MBTL1
SCHEMBL299290 1.00 CYP2C9 (0.50) CYP2C9TSHRPDE4ALMNAL3MBTL1
SCHEMBL3649734 1.00 CYP2C9 (0.50) CYP2C9TSHRPDE4ALMNAL3MBTL1
SCHEMBL37388 1.00 CYP2C9 (0.50) CYP2C9TSHRPDE4ALMNAL3MBTL1
SCHEMBL23723109 1.00 CYP2C9 (0.50) CYP2C9TSHRPDE4ALMNAL3MBTL1
SCHEMBL31338625 1.00 CYP2C9 (0.50) CYP2C9TSHRPDE4ALMNAL3MBTL1
Water SCHEMBL4393893 0.97 CYP2C9 (0.48) CYP2C9TSHRPDE4ALMNAL3MBTL1
SCHEMBL30504628 0.97 CYP2C9 (0.48) CYP2C9TSHRPDE4ALMNAL3MBTL1
SCHEMBL29825289 0.97 CYP2C9 (0.48) CYP2C9TSHRPDE4ALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024054682-A2 ULTRALOW MOLECULAR WEIGHT HEPARIN THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-03-14 WO disclosed
US-20240018177-A1 UTILITY OF NEMATODE SMALL MOLECULES BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH 2024-01-18 US disclosed
US-11849688-B2 Compositions and methods for modulating immunity in plants BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) 2023-12-26 US disclosed
US-11673908-B2 Utility of nematode small molecules CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-06-13 US disclosed
US-20230024046-A1 UTILITY OF NEMATODE SMALL MOLECULES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-01-26 US disclosed
US-20220409650-A1 COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA HOLOCLARA INC (US) 2022-12-29 US disclosed
US-20210246476-A1 BIOSYNTHESIS OF PREPARING NICOTINAMIDE MONONUCLEOTIDE AND DERIVATIVES THEREOF ZHANG YI HENG PERCIVAL (US) 2021-08-12 US disclosed
US-11019776-B2 Compositions and methods for modulating immunity in plants BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) 2021-06-01 US disclosed
US-20210023109-A1 LIPOTECHOIC ACID FOR IMMUNE MODULATION NORTHWESTERN UNIVERSITY 2021-01-28 US disclosed
WO-2020247480-A1 COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA HOLOCLARA, INC. (US) 2020-12-10 WO disclosed
EP-1732384-A1 NOVEL SYNTHETIC C-GLYCOLIPIDS, THEIR SYNTHESIS AND USE TO TREAT INFECTIONS, CANCER AND AUTOIMMUNE DISEASES NEW YORK UNIVERSITY (US) 2006-12-20 EP disclosed
US-20060019246-A1 Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases NEW YORK UNIVERSITY (US) 2006-01-26 US disclosed
WO-2005102049-A1 NOVEL SYNTHETIC C-GLYCOLIPIDS, THEIR SYNTHESIS AND USE TO TREAT INFECTIONS, CANCER AND AUTOIMMUNE DISEASES NEW YORK UNIVERSITY (US) 2005-11-03 WO disclosed
US-20050222048-A1 Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2005-10-06 US disclosed
US-20050192248-A1 Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases NYU MEDICAL CENTER (US) 2005-09-01 US disclosed
EP-1551228-A2 SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES New York University (US) 2005-07-13 EP disclosed
US-20040127429-A1 Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE 2004-07-01 US disclosed
WO-2003105769-A2 SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES NEW YORK UNIVERSITY (US) 2003-12-24 WO disclosed
US-20030162664-A1 Surfactant coated products and methods for their use in promoting plant growth and soil remediation JAR-MAR, INC. 2003-08-28 US disclosed
US-6565860-B1 Agricultural mixtures containing fertilizer JAY-MAR, INC. 2003-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162664-A1 Surfactant coated products and methods for their use in promoting plant growth and soil remediation GMNN, GHDC, GMDS CYP2C9 343/4885TSHR 2611/4885PDE4A 2539/4885
US-11019776-B2 Compositions and methods for modulating immunity in plants SLC11A2, IFNG, STING1 CYP2C9 4705/4885TSHR 4608/4885PDE4A 948/4885
US-20230024046-A1 UTILITY OF NEMATODE SMALL MOLECULES NOD2, MYD88, NOD1 CYP2C9 4641/4885TSHR 4770/4885PDE4A 630/4885
US-20240018177-A1 UTILITY OF NEMATODE SMALL MOLECULES NOD2, MYD88, NOD1 CYP2C9 4641/4885TSHR 4770/4885PDE4A 630/4885
US-20050192248-A1 Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases CD4, CD81, CD69 CYP2C9 4431/4885TSHR 3097/4885PDE4A 4177/4885
US-20040127429-A1 Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases UGT8, UGCG, SGMS1 CYP2C9 1453/4885TSHR 467/4885PDE4A 4642/4885
US-20060019246-A1 Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases CCR8, UGT8, H1-10 CYP2C9 1473/4885TSHR 270/4885PDE4A 4653/4885
US-20220409650-A1 COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA SI, FABP2, ALPI CYP2C9 2291/4885TSHR 4794/4885PDE4A 807/4885
US-20050222048-A1 Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases HACD3, SGMS1, UGCG CYP2C9 2889/4885TSHR 1067/4885PDE4A 3687/4885
US-20210023109-A1 LIPOTECHOIC ACID FOR IMMUNE MODULATION LTA, LRBA, LCLAT1 CYP2C9 4414/4885TSHR 2163/4885PDE4A 2591/4885
US-11849688-B2 Compositions and methods for modulating immunity in plants SLC11A2, IFNG, STING1 CYP2C9 4705/4885TSHR 4608/4885PDE4A 948/4885
US-11673908-B2 Utility of nematode small molecules NOD2, MYD88, NOD1 CYP2C9 4641/4885TSHR 4770/4885PDE4A 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.